2nd study testing a COVID-19 antibody drug has a setback

Advertisement

Advertise with us

For the second time, a study testing an experimental antibody drug for COVID-19 has been paused to investigate a possible safety issue in hospitalized patients.

Read this article for free:


or

Already have an account? Log in here »

To continue reading, please subscribe:

Subscribe and receive a limited-edition Free Press branded hat or tote.

Digital Subscription

One year of digital access for only $205*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles

*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.

To continue reading, please subscribe:

Add Free Press access to your Brandon Sun subscription for only an additional

$1 for the first 4 weeks*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles
Start now

*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.

Hey there, time traveller!
This article was published 30/10/2020 (2129 days ago), so information in it may no longer be current.

For the second time, a study testing an experimental antibody drug for COVID-19 has been paused to investigate a possible safety issue in hospitalized patients.

Regeneron Pharmaceuticals Inc. said Friday that independent monitors had recommended placing on hold enrolment of the most severely ill patients — those who need intense oxygen treatment or breathing machines — because of a potential safety problem and unfavourable balance of risks and benefits.

The study can continue to test the two-antibody drug combo in hospitalized patients who need little or no extra oxygen, the monitors said. Other studies in mild or moderately ill people also are continuing.

In this undated image from video provided by Regeneron Pharmaceuticals on Friday, Oct. 2, 2020, scientists work with a bioreactor at a company facility in New York state, for efforts on an experimental coronavirus antibody drug. Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help the immune system eliminate it. (Regeneron via AP)
In this undated image from video provided by Regeneron Pharmaceuticals on Friday, Oct. 2, 2020, scientists work with a bioreactor at a company facility in New York state, for efforts on an experimental coronavirus antibody drug. Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help the immune system eliminate it. (Regeneron via AP)

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. But it can take several weeks for the most effective ones to form. The experimental drugs aim to help immediately, by supplying concentrated versions of one or two antibodies that worked best against the coronavirus in lab and animal tests.

Earlier this month, a different group of monitors recommended pausing enrolment in a U.S. National Institutes of Health study testing an Eli Lilly antibody drug to investigate a possible safety issue in hospitalized patients. On Monday, the NIH said no safety problem had been verified, but they stopped the study because the drug didn’t seem to work in that situation.

“These kinds of results are informing us about the timing of the benefit,” said Dr. Myron Cohen, a University of North Carolina virologist who advises the government on COVID-19 treatments.

Tests in animals suggest that antibody drugs work best when given early in infection to lower the amount of virus, he said. Once someone is very sick, the drugs may not help, but it’s too soon to know if that’s the case, he said.

Doctors already know that timing can matter when it comes to COVID-19 treatments. Studies suggest that dexamethasone and other steroids can lower the risk of death when given to very sick patients to tamp down an over-active immune system, but they may be harmful for those who are only mildly ill.

Lilly and Regeneron have asked the Food and Drug Administration to allow emergency use of their experimental antibody drugs for mild and moderately ill patients who don’t need hospitalization. President Donald Trump got the Regeneron drug when he was sickened earlier this month.

Regeneron said it would share Friday’s advice from independent monitors with the FDA and leaders of a separate study in the United Kingdom testing its drug in hospitalized patients.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Report Error Submit a Tip

More Stories

Carney’s defence of Lake Ontario carries enormous weight

Niigaan Sinclair 5 minute read Preview

Carney’s defence of Lake Ontario carries enormous weight

Niigaan Sinclair 5 minute read Yesterday at 4:28 PM CDT

For centuries on Turtle Island (North America), explorers, map makers, and political leaders have erased Indigenous place names and substituted them — more often than not — with political, ethnocentric, and self-aggrandizing names.

In recent years, a few places on the continent have had Indigenous names re-established, but as of today, few of the original names are “official.”

So, it was no surprise when U.S. President Donald Trump on Thursday signed an executive order directing the U.S. Department of the Interior and Board on Geographic Names to take steps within 30 days to officially rename Lake Ontario as “Lake America.”

The move may have been a result of the Canada-U.S. trade war and Trump’s pettiness and ego, but it also fits in perfectly with his career.

Read
Yesterday at 4:28 PM CDT

Jets’ Hellebuyck trade request marks pivotal moment for the franchise

Ken Wiebe 6 minute read Preview

Jets’ Hellebuyck trade request marks pivotal moment for the franchise

Ken Wiebe 6 minute read Thursday, Aug. 27, 2026

Connor Hellebuyck has broken his silence in an effort to expedite his departure from the Winnipeg Jets.

In a statement released by agent Ray Petkau on Thursday afternoon, Hellebuyck confirmed he has asked to be moved by the team that chose him in the fifth round of the 2012 NHL draft.

“I have never forgotten June 23, 2012. That’s the day the Winnipeg Jets took a chance on a goalie playing in Odessa, Texas. I gave everything I had from that moment to prove the Jets made the right decision,” Hellebuyck said in the statement.

“Several months ago, I privately requested a trade. I have tried to handle the situation quietly and respectfully, while giving the organization time to explore its options. With training camp approaching, I felt it was important to publicly confirm my request. My position has not changed and I believe moving on is the best path forward for me and my family.”

Read
Thursday, Aug. 27, 2026

Puzzles Palace

1 minute read Monday, Jul. 27, 2026

To solve our puzzles, please subscribe with this special offer: |

Hydro announces CEO out after two years

Chris Kitching 6 minute read Preview

Hydro announces CEO out after two years

Chris Kitching 6 minute read Updated: Yesterday at 9:09 PM CDT

Allan Danroth is out as Manitoba Hydro’s president and CEO — a departure that came as a surprise to some observers — just two years after he was hired.

Danroth left for personal reasons, the Crown corporation’s board chair, Jamie Wilson, said Friday, while announcing chief operating officer Hal Turner as interim president and CEO ahead of a national and international search for a replacement.

“Today’s one of those days where you have a lot of mixed emotions,” Turner told reporters at Hydro’s downtown Winnipeg headquarters. “I just want to say on behalf of all the employees in Manitoba Hydro, we very much appreciate Allan’s leadership over the last two years.”

Turner wouldn’t say whether he will apply to be the next permanent CEO.

Read
Updated: Yesterday at 9:09 PM CDT

Former care home nurse fined $8,000 for ‘disturbing in the extreme’ 2025 incident

Morgan Modjeski 3 minute read Preview

Former care home nurse fined $8,000 for ‘disturbing in the extreme’ 2025 incident

Morgan Modjeski 3 minute read Thursday, Aug. 27, 2026

A former nurse has been fined $8,000 and is facing numerous restrictions after making a mistake “no registered nurse should have made” by inserting 10 centimetres of gauze into a patient’s anus instead of dressing a nearby wound.

Read
Thursday, Aug. 27, 2026

Beware invasive, ‘frightening’ waterhemp

Laura Rance-Unger 4 minute read Preview

Beware invasive, ‘frightening’ waterhemp

Laura Rance-Unger 4 minute read 2:01 AM CDT

There’s a threat lurking on the edge of Manitoba farmers’ fields this fall that’s even scarier than the escalating trade war with their biggest customer.

Provincial extension advisers are warning farmers to watch for a weed known as “tall waterhemp,” which, true to its name, may already be towering above ready-to-harvest crops.

Those wispy tentacles waving in the breeze look pretty innocuous from a distance. But this highly invasive member of the pigweed family produces hundreds of thousands of seeds that are just itching for dispersal through farmers’ combines and across their fields.

Each of those tiny seeds — one small pill container filled halfway holds 44,000 — can produce plants with stems the width of saplings and heights of two to five metres. One or two plants can quickly turn into a patch. If waterhemp takes over a field, it can choke out the growing crop and cut yields by more than 90 per cent.

Read
2:01 AM CDT